

## Special Issue

# The Role of Alternative Splicing in Cancer

### Message from the Guest Editor

Since the original discovery in 1994 that the canonical isoform of the *FAS* gene bound to the mitochondrial membrane is pro-apoptotic, while a soluble isoform is anti-apoptotic, many examples of alternative splicing have been found in which both oncogenic and suppressor isoforms may be produced from the same gene. Aberrant splicing may, therefore, result in oncogenicity in otherwise normal tissue. Due to these circumstances, a great interest in the relationships between alternative splicing and cancer has arisen in the last few years. I am pleased to invite you to contribute to this Special Issue of *Cancers*, which tries to gather relevant papers supporting the increasing importance of those relationships. Both reviews and original manuscripts on mechanisms of alternative splicing, detection and analysis of isoforms, their value as diagnostic and/or prognostic factors, and splicing-related therapeutic approaches will be welcome. We hope that both basic and clinical oncologists will be interested in this exciting field of cancer research. We are looking forward to receiving your contributions.

### Guest Editor

Prof. Dr. Luis Franco

1. Department of Biochemistry and Molecular Biology, Universitat de València, 46010 Valencia, Spain

2. Department of Oncology, Institute of Health Research INCLIVA, 46010 Valencia, Spain

### Deadline for manuscript submissions

closed (15 May 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/119618](https://mdpi.com/si/119618)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)